Singapore markets closed

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
20.12+2.12 (+11.78%)
At close: 04:00PM EST
19.18 -0.94 (-4.67%)
Pre-market: 06:13AM EST
Full screen
Trade prices are not sourced from all markets
Previous close18.00
Bid0.00 x 800
Ask0.00 x 1000
Day's range20.01 - 26.00
52-week range2.84 - 45.00
Avg. volume11,521,231
Market cap384.706M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.75
Earnings date14 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    Why Longeveron Stock Skyrockted 661.2% in November

    Shares of Longeveron (NASDAQ: LGVN) jumped 661.2% in November, according to data from S&P Global Market Intelligence. The stock surged after it was announced that the company received a Rare Pediatric Disease (RPD) designation for its Lomecel-B treatment. Longeveron announced on Nov. 18 that Lomecel-B had received RPD designation for the treatment of hypoplastic left heart syndrome (HLHS) -- a potentially fatally heart condition in infants.

  • Motley Fool

    Is Longeveron a Good Biotech Stock to Buy?

    An American biotechnology company located in Miami of all places has convinced more than a few investors that its cellular therapy candidate can reverse common effects of aging. This November, shares of Longeveron (NASDAQ: LGVN) shot up more than 10-fold. Investors who missed the boat the first time around are wondering if Longeveron the recent slide is an opportunity to buy a potential long-term winner at a relative discount.

  • Motley Fool

    Here's Why Longeveron Is Surging Today

    An orphan drug designation for the treatment of a rare heart condition is pushing the biotech stock higher.